Skip to content
Screener

Incyte INCY EPS (Basic)

EPS (Basic) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Pfizer logo
PfizerPFE
-$0.04-108%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$0.94-10.6%
Gilead Sciences logo
Gilead SciencesGILD
-$8.45-638%
Geron logo
GeronGERN
-$0.020.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$2.47+549%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24B+58.2%
Enterprise value$20.05B+51.3%
P/E14.9×-2.5×
P/S4.1×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Provision for income taxes165,909153,013206,179229,000
Net income$585,605$404,999$888,935$563,202
Net income per share:
Basic$2.92$2.09$4.45$2.91
Diluted$2.81$2.04$4.28$2.84
Shares used in computing net income per share:
Basic200,378193,995199,860193,853
Diluted208,216198,744207,670198,526

Item 1. Financial Statements

FAQ

What is Incyte's EPS (basic)?
Incyte (INCY) reported EPS (basic) of $2.92 in Q2 2026.
How has Incyte's EPS (basic) changed year-over-year?
Incyte's EPS (basic) increased by 39.7% year-over-year, from $2.09 to $2.92.
What is the long-term trend for Incyte's EPS (basic)?
Over 4 years (2021 to 2025), Incyte's EPS (basic) has grown at a 11.3% compound annual growth rate (CAGR), from $4.29 to $6.59.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Incyte's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude